The Verastem’s (VSTM) “Buy” Rating Reaffirm at Cantor Fitzgerald

The Verastem’s (VSTM) “Buy” Rating Reaffirm at Cantor Fitzgerald

Verastem Inc (NASDAQ:VSTM)‘s stock had its “buy” rating reissued by research analysts at Cantor Fitzgerald in a research note issued on Wednesday.

A number of other equities research analysts have also issued reports on the company. HC Wainwright set a $5.00 price target on Verastem and gave the stock a “buy” rating in a research note on Tuesday, October 4th. Zacks Investment Research lowered Verastem from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Finally, Jefferies Group restated a “hold” rating and set a $1.50 price objective on shares of Verastem in a research report on Friday, August 5th.

Shares of Verastem (NASDAQ:VSTM) traded up 3.35% on Wednesday, reaching $1.23. The company had a trading volume of 29,536 shares. The firm’s market capitalization is $45.50 billion. The stock’s 50 day moving average is $1.29 and its 200 day moving average is $1.35. Verastem has a 52 week low of $1.05 and a 52 week high of $2.43.

Verastem (NASDAQ:VSTM) last issued its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.03. On average, equities analysts anticipate that Verastem will post ($0.92) EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Verastem by 9.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 253,675 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 22,600 shares during the last quarter. Panagora Asset Management Inc. increased its position in shares of Verastem by 3.5% in the third quarter. Panagora Asset Management Inc. now owns 457,577 shares of the biopharmaceutical company’s stock worth $609,000 after buying an additional 15,612 shares during the last quarter. D. E. Shaw & Co. Inc. increased its position in shares of Verastem by 8.2% in the third quarter. D. E. Shaw & Co. Inc. now owns 572,639 shares of the biopharmaceutical company’s stock worth $762,000 after buying an additional 43,609 shares during the last quarter. Emerald Acquisition Ltd. increased its position in shares of Verastem by 4.8% in the third quarter. Emerald Acquisition Ltd. now owns 144,792 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 6,612 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in shares of Verastem during the second quarter worth approximately $153,000.

Verastem Company Profile

Related posts

Leave a Comment